SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding
PLEASANTON, CA, March 29, 2025 (GLOBE NEWSWIRE) — SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal Phase 3 REVERSE-IT trial designed to study